secwatch.observer — SEC 8-K summary
======================================

Issuer:     PETMED EXPRESS INC (PETS)
CIK:        0001040130
Form:       8-K
Filed at:   2024-06-11T23:59:59+00:00
Accession:  0001040130-24-000043
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PetMed Express Q4 net loss widens to $5.0M; FY net loss $7.5M vs prior year profit
--------------------------------------------------------------------------------

- Q4 net sales $66.5M (+6.6% YoY) driven by PetCareRx acquisition; legacy PetMeds sales declined.
- Q4 net loss $5.0M ($0.25 diluted EPS) vs loss $0.2M ($0.01) in prior year quarter.
- FY 2024 net loss $7.5M ($0.37 diluted EPS) vs net income $5.1M ($0.25) in FY 2023.
- Adjusted EBITDA Q4 $0.5M (from $3.6M); FY $8.2M (from $19.8M) as G&A and marketing rose.
- CEO cites challenging macro environment and new Order Management System slowdown in Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1040130/000104013024000043/0001040130-24-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1040130/000104013024000043/pets-20240611.htm
  HTML page:      https://secwatch.observer/filing/0001040130-24-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer